Loading...
XKRX
002720
Market cap47mUSD
Jul 10, Last price  
3,455.00KRW
1D
2.52%
1Q
-28.84%
Jan 2017
-7.87%
Name

Kukje Pharma Co Ltd

Chart & Performance

D1W1MN
XKRX:002720 chart
P/E
12.83
P/S
0.42
EPS
269.27
Div Yield, %
0.89%
Shrs. gr., 5y
-0.86%
Rev. gr., 5y
6.12%
Revenues
175.50b
+12.16%
97,272,857,000103,756,103,000121,637,704,000122,564,775,000131,308,308,000104,857,016,220126,768,060,540120,461,297,420122,426,376,880117,636,991,850120,684,005,940123,310,224,120107,681,163,420111,121,601,010130,394,720,790119,745,568,740126,583,402,930135,372,690,530156,462,823,000175,496,223,500
Net income
5.70b
+9.46%
6,143,517,0006,224,645,0006,604,140,0006,859,001,0004,313,552,000927,806,000-18,940,084,0002,125,167,000-6,932,106,230-5,942,878,860773,061,5501,092,249,3102,192,621,150-4,761,811,9502,203,001,020-1,555,791,2803,557,333,460-8,415,187,4565,205,175,0005,697,660,529
CFO
5.84b
+48.11%
4,829,648,0009,543,098,0001,072,167,0005,977,556,000-1,550,183,00017,385,055,2901,579,978,970-4,595,893,280-61,109,660-5,080,183,75016,098,588,910786,104,14013,248,711,0703,603,683,0005,099,946,0209,597,051,8106,503,789,1303,575,183,9013,939,913,0005,835,456,501
Dividend
Mar 13, 202530 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

KUKJE PHARMA Co. Ltd. engages in the manufacture, sale, and distribution of pharmaceutical, cosmetics, and healthcare products. Its products include cephalosporins, penicillins, quinolones, aminoglycosides, macrolides, antibiotics, and antifungal and antiviral agents. The company was founded on July 27, 1959 and is headquartered in Seongnam, South Korea.
URL
http://www.kukjepharm.co.kr
IPO date
Dec 27, 1975
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT